1-19 of 19
Hiddo J.L. Heerspink
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial

Ellen M. Apperloo, Hiddo J.L. Heerspink, Annemarie B. van der Aart, Dennis Rouw, Daniël H. van Raalte, Klaas Hoogenberg, Niels Jongs, Marcel H.A. Muskiet
Journal: Diabetes Care
Diabetes Care dc242244
https://doi.org/10.2337/dc24-2244
Published: 10 January 2025
View article titled, Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial
Open the PDF for Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial in another window
Journal Articles

Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023;46:593–601

Viktor Rotbain Curovic, Frederik Persson, Niels Jongs, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2024;47(2):e21
https://doi.org/10.2337/dci23-0046
Published: 19 January 2024
View article titled, Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023;46:593–601
Open the PDF for Response to Comment on Curovic et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care 2023;46:593–601 in another window
Journal Articles

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis

Hiddo J.L. Heerspink, Naveed Sattar, Imre Pavo, Axel Haupt, Kevin L. Duffin, Zhengyu Yang, Russell J. Wiese, Jonathan M. Wilson, Andrea Hemmingway, David Z.I. Cherney, Katherine R. Tuttle
Journal: Diabetes Care
Diabetes Care 2023;46(8):1501–1506
https://doi.org/10.2337/dc23-0261
Published: 02 June 2023
View article titled, Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
Open the PDF for Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis in another window
Journal Articles

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3

Vikas S. Sridhar, Hiddo J.L. Heerspink, Michael J. Davies, Phillip Banks, Manon Girard, Satish K. Garg, David Z.I. Cherney
Journal: Diabetes Care
Diabetes Care 2023;46(7):e133–e135
https://doi.org/10.2337/dc23-0129
Published: 12 May 2023
View article titled, The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
Open the PDF for The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3 in another window
Journal Articles

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Hiddo J.L. Heerspink, Ellen Apperloo, Melanie Davies, Dror Dicker, Kristian Kandler, Julio Rosenstock, Rasmus Sørrig, Jack Lawson, Niels Zeuthen, David Cherney
Journal: Diabetes Care
Diabetes Care 2023;46(4):801–810
https://doi.org/10.2337/dc22-1889
Published: 17 February 2023
View article titled, Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Open the PDF for Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials in another window
Journal Articles

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Jelle M. Beernink, Frederik Persson, Niels Jongs, Gozewijn D. Laverman, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2023;46(3):602–607
https://doi.org/10.2337/dc22-1514
Published: 20 January 2023
View article titled, Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
Open the PDF for Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study in another window
Journal Articles

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial

Viktor Rotbain Curovic, Niels Jongs, Marjolein Y.A.M. Kroonen, Emilie H. Zobel, Tine W. Hansen, Taha Sen, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2023;46(3):593–601
https://doi.org/10.2337/dc22-1699
Published: 18 January 2023
View article titled, Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial
Open the PDF for Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial in another window
Journal Articles

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2022;45(11):2644–2652
https://doi.org/10.2337/dc22-0866
Published: 22 September 2022
View article titled, Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Open the PDF for Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS in another window
Journal Articles

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P.H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine
Journal: Diabetes Care
Diabetes Care 2022;45(10):2350–2359
https://doi.org/10.2337/dc22-0382
Published: 23 August 2022
View article titled, Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Open the PDF for Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial in another window
Journal Articles

Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes

Morgan E. Grams, Nigel J. Brunskill, Shoshana H. Ballew, Yingying Sang, Josef Coresh, Kunihiro Matsushita, Aditya Surapaneni, Samira Bell, Juan J. Carrero, Gabriel Chodick, Marie Evans, Hiddo J.L. Heerspink, Lesley A. Inker, Kunitoshi Iseki, Philip A. Kalra, H. Lester Kirchner, Brian J. Lee, Adeera Levin, Rupert W. Major, James Medcalf, Girish N. Nadkarni, David M.J. Naimark, Ana C. Ricardo, Simon Sawhney, Manish M. Sood, Natalie Staplin, Nikita Stempniewicz, Benedicte Stengel, Keiichi Sumida, Jamie P. Traynor, Jan van den Brand, Chi-Pang Wen, Mark Woodward, Jae Won Yang, Angela Yee-Moon Wang, Navdeep Tangri, for the CKD Prognosis Consortium
Journal: Diabetes Care
Diabetes Care 2022;45(9):2055–2063
https://doi.org/10.2337/dc22-0698
Published: 20 July 2022
View article titled, Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
Open the PDF for Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes in another window
Journal Articles

Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database

Hajime Nagasu, Yuichiro Yano, Hiroshi Kanegae, Hiddo J.L. Heerspink, Masaomi Nangaku, Yosuke Hirakawa, Yuka Sugawara, Naoki Nakagawa, Yuji Tani, Jun Wada, Hitoshi Sugiyama, Kazuhiko Tsuruya, Toshiaki Nakano, Shoichi Maruyama, Takashi Wada, Kunihiro Yamagata, Ichiei Narita, Kouichi Tamura, Motoko Yanagita, Yoshio Terada, Takashi Shigematsu, Tadashi Sofue, Takafumi Ito, Hirokazu Okada, Naoki Nakashima, Hiromi Kataoka, Kazuhiko Ohe, Mihoko Okada, Seiji Itano, Akira Nishiyama, Eiichiro Kanda, Kohjiro Ueki, Naoki Kashihara
Journal: Diabetes Care
Diabetes Care 2021;44(11):2542–2551
https://doi.org/10.2337/dc21-1081
Published: 18 October 2021
View article titled, Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
Open the PDF for Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database in another window
Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2021;44(8):1805–1815
https://doi.org/10.2337/dc21-0076
Published: 11 August 2021
View article titled, The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Open the PDF for The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 in another window
Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Frederik Persson, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur V. Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2021;44(8):1894–1897
https://doi.org/10.2337/dc21-0300
Published: 28 June 2021
View article titled, Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Open the PDF for Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial in another window
Journal Articles

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

Frederik Persson, Stephen C. Bain, Ofri Mosenzon, Hiddo J.L. Heerspink, Johannes F.E. Mann, Richard Pratley, Itamar Raz, Thomas Idorn, Søren Rasmussen, Bernt Johan von Scholten, Peter Rossing
Journal: Diabetes Care
Diabetes Care 2021;44(4):1020–1026
https://doi.org/10.2337/dc20-1622
Published: 27 January 2021
View article titled, Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
Open the PDF for Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial in another window
Journal Articles

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Rosalie A. Scholtes, Marcel H.A. Muskiet, Michiel J.B. van Baar, Anne C. Hesp, Peter J. Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H. van Raalte, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2021;44(2):440–447
https://doi.org/10.2337/dc20-2604
Published: 14 December 2020
View article titled, Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
Open the PDF for Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial in another window
Journal Articles

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

Daniël H. van Raalte, Petter Bjornstad, Frederik Persson, David R. Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J.L. Heerspink, David Cherney
Journal: Diabetes Care
Diabetes Care 2019;42(10):1921–1929
https://doi.org/10.2337/dc19-0937
Published: 01 August 2019
View article titled, The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
Open the PDF for The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL

Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Weifeng Tang, David W. Boulton, Srinivas Bachina, Robert D. Fox, Peter Fenici, Marcus Thuresson, Robert J. Mentz, Adrian F. Hernandez, Rury R. Holman
Journal: Diabetes Care
Diabetes Care 2019;42(2):318–326
https://doi.org/10.2337/dc18-1871
Published: 06 December 2018
View article titled, Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Open the PDF for Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL in another window
Includes: Supplementary data
Journal Articles

Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes

Gert Mayer, Hiddo J.L. Heerspink, Constantin Aschauer, Andreas Heinzel, Georg Heinze, Alexander Kainz, Judith Sunzenauer, Paul Perco, Dick de Zeeuw, Peter Rossing, Michelle Pena, Rainer Oberbauer
Journal: Diabetes Care
Diabetes Care 2017;40(3):391–397
https://doi.org/10.2337/dc16-2202
Published: 11 January 2017
View article titled, Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes
Open the PDF for Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography–Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes

Stefanie A. de Boer, Marieke C. Hovinga-de Boer, Hiddo J.L. Heerspink, Joop D. Lefrandt, Arie M. van Roon, Helen L. Lutgers, Andor W.J.M. Glaudemans, Pieter W. Kamphuisen, Riemer H.J.A. Slart, Douwe J. Mulder
Journal: Diabetes Care
Diabetes Care 2016;39(8):1440–1447
https://doi.org/10.2337/dc16-0327
Published: 08 June 2016
View article titled, Arterial Stiffness Is Positively Associated With <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography–Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes
Open the PDF for Arterial Stiffness Is Positively Associated With <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography–Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes in another window
Includes: Supplementary data